VIVUS (VVUS) Peers Tick Higher Amid Positive Qsymia Data (ARNA) (OREX)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
VIVUS, Inc. (VVUS) Qsymia Prescriptions Show Gains During Slow Holiday Week (ARNA) (OREX)
February 4, 2013 10:45 AM ESTVIVUS, Inc. (Nasdaq: VVUS) is lower on the session amid new data for prescriptions of its weight-loss pill, Qsymia.
According to Bloomberg Industries, Qsymia prescriptions rose 24 percent to 2,859 last week. Data comes from Symphony Health Solutions.
Bloomberg also noted that... More
VIVUS (VVUS) Reports Publication of Signifianct Data from Recent Qsymia Study
February 1, 2013 7:15 AM ESTVIVUS, Inc. (Nasdaq: VVUS) announces the publication of a study concluding that weight loss resulting from treatment with Qsymia (phentermine and topiramate extended-release) capsules CIV led to significant improvements in cholesterol, blood pressure and triglycerides in obese and overweight patients experiencing one or more of these... More
